We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences recently announced that it would no longer pursue FDA approval for Jyseleca and it downgraded a multibillion-dollar development pact with Galapagos. Read More
Merus will spearhead the early development of oncology drugs, using its proprietary drug platform, while Eli Lilly’s Loxo Oncology subsidiary will provide additional research and marketing. Read More
The system does not require pre-operative imaging to accurately resect bones and position knee implants, and offers advanced planning capabilities, the company said. Read More
The unit is compatible with Senhance Surgical Systems already installed and with third-party vision systems that are currently supported by Senhance. Read More